CRISPR-Cas9-assisted recombineering in Lactobacillus reuteri

被引:301
作者
Oh, Jee-Hwan [1 ]
van Pijkeren, Jan-Peter [1 ]
机构
[1] Univ Wisconsin, Dept Food Sci, Madison, WI 53706 USA
关键词
LACTIC-ACID BACTERIA; LACTOCOCCUS-LACTIS; CRISPR/CAS; ELECTROPORATION; TRANSFORMATION; RECOMBINATION; REPLICATION; PLANTARUM; STRAINS; SYSTEMS;
D O I
10.1093/nar/gku623
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Clustered regularly interspaced palindromic repeats (CRISPRs) and the CRISPR-associated (Cas) nuclease protect bacteria and archeae from foreign DNA by site-specific cleavage of incoming DNA. Type-II CRISPR-Cas systems, such as the Streptococcus pyogenes CRISPR-Cas9 system, can be adapted such that Cas9 can be guided to a user-defined site in the chromosome to introduce double-stranded breaks. Here we have developed and optimized CRISPR-Cas9 function in the lactic acid bacterium Lactobacillus reuteri ATCC PTA 6475. We established proof-of-concept showing that CRISPR-Cas9 selection combined with single-stranded DNA (ssDNA) recombineering is a realistic approach to identify at high efficiencies edited cells in a lactic acid bacterium. We show for three independent targets that subtle changes in the bacterial genome can be recovered at efficiencies ranging from 90 to 100%. By combining CRISPR-Cas9 and recombineering, we successfully applied codon saturation mutagenesis in the L. reuteri chromosome. Also, CRISPR-Cas9 selection is critical to identify low-efficiency events such as oligonucleotide-mediated chromosome deletions. This also means that CRISPR-Cas9 selection will allow identification of recombinant cells in bacteria with low recombineering efficiencies, eliminating the need for ssDNA recombineering optimization procedures. We envision that CRISPR-Cas genome editing has the potential to change the landscape of genome editing in lactic acid bacteria, and other Gram-positive bacteria.
引用
收藏
页数:11
相关论文
共 46 条
[1]   TRANSFORMATION OF LACTOBACILLUS-REUTERI WITH ELECTROPORATION - STUDIES ON THE ERYTHROMYCIN RESISTANCE PLASMID PLUL631 [J].
AHRNE, S ;
MOLIN, G ;
AXELSSON, L .
CURRENT MICROBIOLOGY, 1992, 24 (04) :199-205
[2]   Probiotics and health: An evidence-based review [J].
Aureli, Paolo ;
Capurso, Lucio ;
Castellazzi, Anna Maria ;
Clerici, Mario ;
Giovannini, Marcello ;
Morelli, Lorenzo ;
Poli, Andrea ;
Pregliasco, Fabrizio ;
Salvini, Filippo ;
Zuccotti, Gian Vincenzo .
PHARMACOLOGICAL RESEARCH, 2011, 63 (05) :366-376
[3]   CRISPR-Cas systems and RNA-guided interference [J].
Barrangou, Rodolphe .
WILEY INTERDISCIPLINARY REVIEWS-RNA, 2013, 4 (03) :267-278
[4]   Probiotic L. reuteri Treatment Prevents Bone Loss in a Menopausal Ovariectomized Mouse Model [J].
Britton, Robert A. ;
Irwin, Regina ;
Quach, Darin ;
Schaefer, Laura ;
Zhang, Jing ;
Lee, Taehyung ;
Parameswaran, Narayanan ;
McCabe, Laura R. .
JOURNAL OF CELLULAR PHYSIOLOGY, 2014, 229 (11) :1822-1830
[5]  
Bron Peter A, 2011, Bioeng Bugs, V2, P80, DOI 10.4161/bbug.2.2.13910
[6]  
Cha R S, 1992, PCR Methods Appl, V2, P14
[7]   Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases [J].
Cho, Seung Woo ;
Kim, Sojung ;
Kim, Yongsub ;
Kweon, Jiyeon ;
Kim, Heon Seok ;
Bae, Sangsu ;
Kim, Jin-Soo .
GENOME RESEARCH, 2014, 24 (01) :132-141
[8]   The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems [J].
Chylinski, Krzysztof ;
Le Rhun, Anais ;
Charpentier, Emmanuelle .
RNA BIOLOGY, 2013, 10 (05) :726-737
[9]   Review article: probiotics for the treatment of irritable bowel syndrome - focus on lactic acid bacteria [J].
Clarke, G. ;
Cryan, J. F. ;
Dinan, T. G. ;
Quigley, E. M. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 35 (04) :403-413
[10]   Multiplex Genome Engineering Using CRISPR/Cas Systems [J].
Cong, Le ;
Ran, F. Ann ;
Cox, David ;
Lin, Shuailiang ;
Barretto, Robert ;
Habib, Naomi ;
Hsu, Patrick D. ;
Wu, Xuebing ;
Jiang, Wenyan ;
Marraffini, Luciano A. ;
Zhang, Feng .
SCIENCE, 2013, 339 (6121) :819-823